CME Group, Inc.

Is CME Group, Inc. overvalued or undervalued?

As of June 30, 2025, CME Group, Inc. is fairly valued with a P/E ratio of 27, an EV to EBITDA of 22.04, and a Price to Book Value of 3.66, showing competitive positioning despite recent stock performance lagging behind the S&P 500 over longer periods.

As of 30 June 2025, the valuation grade for CME Group, Inc. has moved from attractive to fair, indicating a shift in its perceived value. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 27, an EV to EBITDA of 22.04, and a Price to Book Value of 3.66. In comparison to peers, CME Group's P/E ratio is higher than The Charles Schwab Corp. at 25.67 and lower than The Goldman Sachs Group, Inc. at 41.63, suggesting a competitive position within the industry.<BR><BR>In terms of recent performance, CME Group's stock has returned 20.48% over the past year, slightly outperforming the S&P 500's return of 17.14%. However, over longer periods, such as the 3-year and 5-year returns, CME Group has lagged significantly behind the S&P 500, which returned 70.41% and 96.61%, respectively. This discrepancy may indicate that while the company is currently fairly valued, it faces challenges in maintaining competitive growth relative to broader market indices.

Is CME Group, Inc. technically bullish or bearish?

As of August 12, 2025, CME Group's technical trend is mildly bullish, with mixed indicators across different time frames, while it has underperformed the S&P 500 recently but outperformed it year-to-date and over the past year.

As of 12 August 2025, the technical trend for CME Group, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST are both mildly bearish, while the monthly MACD and KST are bullish. The daily moving averages indicate a mildly bullish stance. Bollinger Bands show a bearish signal on the weekly chart but a mildly bullish signal on the monthly chart. Dow Theory is mildly bearish on both weekly and monthly time frames. <BR><BR>In terms of performance, CME Group has underperformed the S&P 500 over the past week and month, with returns of -0.68% and -3.63% compared to 1.05% and 2.33% for the index, respectively. However, it has outperformed the S&P 500 on a year-to-date and one-year basis, with returns of 12.21% and 20.48% versus 12.22% and 17.14%. Over three and five years, CME Group has significantly lagged behind the S&P 500, with returns of 36.04% and 54.15% compared to 70.41% and 96.61%. Overall, the current technical stance is mildly bullish.

How big is CME Group, Inc.?

As of Jun 18, CME Group, Inc. has a market capitalization of $97.19 billion, with net sales of $6.28 billion and a net profit of $3.63 billion over the last four quarters. The company also reported total assets of $137.59 billion and shareholder's funds of $26.49 billion as of Dec 24.

As of Jun 18, CME Group, Inc. has a market capitalization of 97,188.89 million, classifying it as a Large Cap company.<BR><BR>As of the latest four quarters, CME Group, Inc. reported net sales of 6,284.50 million and a net profit of 3,629.50 million.<BR><BR>As of Dec 24, the company reported shareholder's funds of 26,486.90 million and total assets amounting to 137,589.00 million.

What does CME Group, Inc. do?

CME Group, Inc. operates in the capital markets, offering a variety of futures and options products across all asset classes. As of March 2025, it reported net sales of $1.642 billion and a net profit of $950 million, with a market cap of approximately $97.19 billion.

Overview:<BR>CME Group, Inc. operates in the capital markets industry, providing a range of products across all asset classes, including futures and options.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,642 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 950 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 97,188.89 Million (Large Cap) <BR><BR>Key Metrics:<BR>P/E: 27.00 <BR>Dividend Yield: 300.75% <BR>Debt Equity: -999,999.00 <BR>Return on Equity: 13.43% <BR>Price to Book: 3.60 <BR><BR>Contact Details:<BR>Address: 20 S Wacker Dr, CHICAGO IL: 60606-7431 <BR>Tel: 1 312 9301000 <BR>Website: https://www.cmegroup.com/

Should I buy, sell or hold CME Group, Inc.?

Who are in the management team of CME Group, Inc.?

As of March 2022, the management team of CME Group, Inc. includes Executive Chairman and CEO Terrence Duffy, Vice Chairman Charles Carey, Lead Independent Director Daniel Glickman, and several Independent Directors: Michael Spencer, Timothy Bitsberger, Dennis Chookaszian, and Elizabeth Cook. This team is responsible for the company's strategic direction and governance.

As of March 2022, the management team of CME Group, Inc. includes the following individuals:<BR><BR>- Hon. Terrence Duffy, who serves as the Executive Chairman of the Board and Chief Executive Officer.<BR>- Mr. Charles Carey, who is the Vice Chairman of the Board.<BR>- Mr. Daniel Glickman, who holds the position of Lead Independent Director.<BR>- Mr. Michael Spencer, who is a Director.<BR>- Mr. Timothy Bitsberger, who serves as an Independent Director.<BR>- Mr. Dennis Chookaszian, who is also an Independent Director.<BR>- Ms. Elizabeth Cook, who is another Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.